TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Scorpion alleged the company operates a "mafia-style" scheme involving off-label device misuse and customer attrition, as it set TransMedics target price of $0. “Investors sense something is ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

TransMedics Group's management had not responded publicly to Scorpion Capital's report at the time of this writing. Some of Scorpion's allegations might seem questionable to anyone who has ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.